Research Summary
Anti-obesity prescription drugs are medications specifically used to treat obesity, helping to reduce body weight through various mechanisms, typically for patients who cannot effectively lose weight through diet and exercise alone. These drugs may work by suppressing appetite, increasing metabolic rate, or blocking fat absorption. Common types of anti-obesity drugs include selective 5-HT2C receptor agonists, fat absorption inhibitors, and central nervous system suppressants. Anti-obesity drugs are usually prescribed under the guidance of a healthcare professional, as they may have side effects and require careful monitoring for potential drug interactions. In most cases, these medications need to be used in conjunction with a low-calorie diet and increased physical activity for optimal results. Additionally, certain anti-obesity drugs may be suitable for obese patients with comorbid conditions such as diabetes, hypertension, or high cholesterol, helping to manage these concurrent issues. However, anti-obesity medications are not intended as a long-term solution, and the core of weight management remains adopting a healthy lifestyle.
According to WENKH research statistics, the global Anti-Obesity Prescription Drugs market size will reach Million USD in 2026 and is projected to reach Million USD by 2033, with a CAGR of % (2026-2033). Among them, the Asia-Pacific Anti-Obesity Prescription Drugs market is undergoing rapid changes, reaching Million USD in 2026, accounting for approximately % of the global market share. It is projected to reach Million USD by 2033.
The global Anti-Obesity Prescription Drugs market is highly competitive, with key market players including F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, etc. This report categorizes the competitive landscape of the global Anti-Obesity Prescription Drugs market into three tiers based on annual revenue, with the top three market players holding approximately % of the total market share.
This report provides an in-depth analysis of the global Anti-Obesity Prescription Drugs market, including market size, price trends, market status and future development prospects. It particularly focuses on the market share, product characteristics, pricing, sales revenue, and gross profit margin of major players in the global Anti-Obesity Prescription Drugs industry. Additionally, this report provides an in-depth analysis of the market status and future development trends of different product segments of Anti-Obesity Prescription Drugs and their downstream application fields.
In terms of data, this report includes a comprehensive time-series dataset. The historical data spans from 2021 to 2025, providing a solid foundation for analyzing past market trends. The year 2026 is used as a base year to accurately assess the current market landscape. Forecast data covers the period from 2027 to 2033, utilizing scientific analysis methods and models to offer forward-looking predictions and insights into the market's future development. This provides valuable reference information for industry participants and stakeholders.
The report covers countries including United States, China, Germany, Japan, France, South Korea, United Kingdom, India, Italy, Brazil, Mexico, Indonesia, Vietnam and South Africa. It particularly focuses on the sales revenue of Anti-Obesity Prescription Drugs in these countries, as well as the product segmentation and downstream application market size of each country. The report provides an in-depth analysis of the regional distribution and future development trends of the Anti-Obesity Prescription Drugs market. By considering local policies, this report evaluates the market prospects of Anti-Obesity Prescription Drugs in each country, aiming to help companies gain a comprehensive understanding of the industry characteristics and development potential in different regions, optimize regional business layout, and develop precise market strategies to achieve global development goals.
This report places a strong emphasis on data quality and reliability, utilizing diverse and extensive data sources to ensure the accuracy and validity of the information presented. Primary data collection involves multiple channels, including in-depth interviews with senior executives, industry experts, supply chain stakeholders, and end consumers. These interviews provide key insights into corporate strategic planning, industry policy interpretation, supply chain dynamics, and end-user experiences. Secondary data sources cover a wide range of authoritative statistics from government agencies, customs databases, industry associations, third-party paid databases, brokerage research reports, academic research findings, corporate annual reports, financial statements, real-time news updates, and relevant information from international organizations. These data sources serve as a solid foundation for verification and analysis.
Companies Covered
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Product Segment
Wegovy
Saxenda
Zepbound
Xenical
Others
Product Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Chapter Scope
Chapter 1: Product Statistical Scope, Product Segmentation Types and Downstream Applications, Overall Market Size, Current Status and Development Prospects
Chapter 2: Global Anti-Obesity Prescription Drugs Industry Chain Analysis
Chapter 3: Global Anti-Obesity Prescription Drugs Industry Environment Analysis and Porter's Five Forces Analysis
Chapter 4: Analysis of the Competitive Landscape of Major Companies in the Global Anti-Obesity Prescription Drugs Market (Market Share, Product Revenue Comparison, Tier Division, Corporate Expansion and M&A Trends)
Chapter 5: Analysis of Global Major Companies (Company Profiles, Product Specifications and Features, Product Revenue and Product Gross Profit Margin)
Chapter 6: Global Anti-Obesity Prescription Drugs Market Analysis by Countries, Product Segment and Downstream Application
Chapter 7: United States Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 8: China Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 9: Germany Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 10: Japan Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 11: France Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 12: South Korea Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 13: United Kingdom Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 14: India Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 15: Italy Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 16: Brazil Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 17: Mexico Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 18: Indonesia Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 19: Vietnam Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 20: South Africa Anti-Obesity Prescription Drugs Market Size, Product Segment, Downstream Application Analysis
Chapter 21: Research Conclusion
Chapter 22: Methodology and Data Source
Purpose and Value of the Report
Market Trend Insights: Analyze industry trends, market dynamics, and future growth potential to help companies forecast changes and develop strategic plans.
Competitive Landscape Analysis: Understand key players' revenue segmentation, strategies, market share, and business models to guide competitive decisions.
Investment Decision Support: Provide feasibility analysis through market size, growth rate, demand trends, and potential risks for informed investment decisions.
Target Customer and Demand Analysis: Examine consumer behavior, purchasing preferences, and pain points to optimize products and improve market penetration.
Policy and Regulatory Insights: Interpret relevant industry policies to ensure compliance and mitigate regulatory risks.
Business Model Optimization: Offer data-driven suggestions for enhancing business models and improving profitability.
Table of Content
1 Anti-Obesity Prescription Drugs Market Overview
1.1 Product Definition Introduction
1.2 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis (2021-2033)
1.3 Anti-Obesity Prescription Drugs Market Status and Development Prospects
1.3.1 Anti-Obesity Prescription Drugs Market Status
1.3.2 Anti-Obesity Prescription Drugs Industry Development Prospects
1.4 Anti-Obesity Prescription Drugs Market Overview by Product Segment
1.4.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Segment: 2021 VS 2026 VS 2033
1.4.2 Wegovy
1.4.3 Saxenda
1.4.4 Zepbound
1.4.5 Xenical
1.4.6 Others
1.5 Anti-Obesity Prescription Drugs Market Overview by Product Application
1.5.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Application: 2021 VS 2026 VS 2033
1.5.2 Hospitals Pharmacies
1.5.3 Retail Pharmacies
1.5.4 E-commerce
2 Anti-Obesity Prescription Drugs Industry Supply Chain Analysis
2.1 Anti-Obesity Prescription Drugs Supply Chain
2.2 Anti-Obesity Prescription Drugs Midstream Suppliers
2.3 Anti-Obesity Prescription Drugs Downstream Customers
2.4 Anti-Obesity Prescription Drugs Sales Channel Analysis
3 Anti-Obesity Prescription Drugs Market Environment Analysis
3.1 Anti-Obesity Prescription Drugs Industry Policy Analysis
3.2 Anti-Obesity Prescription Drugs Emerging Technology Trends in the Industry
3.3 Anti-Obesity Prescription Drugs Restraining Factors Analysis
3.4 Anti-Obesity Prescription Drugs Market Porter's Five Forces Analysis
3.4.1 Competitive Rivalry
3.4.2 Threat of New Entrants
3.4.3 Bargaining Power of Suppliers
3.4.4 Bargaining Power of Buyers
3.4.5 Threat of Substitute Products or Services
4 Global Anti-Obesity Prescription Drugs Market Players Competition Landscape
4.1 Global Anti-Obesity Prescription Drugs Market Revenue by Key Players (2021-2026)
4.2 Global Anti-Obesity Prescription Drugs Market Position by Key Players
4.3 Global Key Players Headquarter and Key Area Served
4.4 Global Anti-Obesity Prescription Drugs Market Expansion and M&A Dynamic
5 In-depth Analysis of Key Players
5.1 F Hoffmann La Roche Ltd
5.1.1 F Hoffmann La Roche Ltd Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Features
5.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.2 Orexigen Therapeutics
5.2.1 Orexigen Therapeutics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Features
5.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.3 Novo Nordisk A/s
5.3.1 Novo Nordisk A/s Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Features
5.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.4 Arena Pharmaceuticals
5.4.1 Arena Pharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Features
5.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.5 Glaxosmithkline
5.5.1 Glaxosmithkline Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Features
5.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.6 Vivus
5.6.1 Vivus Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.6.2 Vivus Anti-Obesity Prescription Drugs Product Features
5.6.3 Vivus Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.7 Boehringer Ingelheim
5.7.1 Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Features
5.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
5.8 Alizyme
5.8.1 Alizyme Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.8.2 Alizyme Anti-Obesity Prescription Drugs Product Features
5.8.3 Alizyme Anti-Obesity Prescription Drugs Product Revenue and Gross Margin Analysis (2021-2026)
6 Global Anti-Obesity Prescription Drugs Market Analysis by Countries, by Product Segment and Application
6.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast by Countries: 2021 VS 2026 VS 2033
6.1.1 Global Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026)
6.1.2 Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033)
6.2 Global Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
6.3 Global Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
7 United States Anti-Obesity Prescription Drugs Market Analysis
7.1 United States Anti-Obesity Prescription Drugs Market Prospects
7.2 United States Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
7.3 United States Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
8 China Anti-Obesity Prescription Drugs Market Analysis
8.1 China Anti-Obesity Prescription Drugs Market Prospects
8.2 China Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
8.3 China Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
9 Germany Anti-Obesity Prescription Drugs Market Analysis
9.1 Germany Anti-Obesity Prescription Drugs Market Prospects
9.2 Germany Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
9.3 Germany Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
10 Japan Anti-Obesity Prescription Drugs Market Analysis
10.1 Japan Anti-Obesity Prescription Drugs Market Prospects
10.2 Japan Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
10.3 Japan Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
11 France Anti-Obesity Prescription Drugs Market Analysis
11.1 France Anti-Obesity Prescription Drugs Market Prospects
11.2 France Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
11.3 France Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
12 South Korea Anti-Obesity Prescription Drugs Market Analysis
12.1 South Korea Anti-Obesity Prescription Drugs Market Prospects
12.2 South Korea Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
12.3 South Korea Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
13 United Kingdom Anti-Obesity Prescription Drugs Market Analysis
13.1 United Kingdom Anti-Obesity Prescription Drugs Market Prospects
13.2 United Kingdom Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
13.3 United Kingdom Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
14 India Anti-Obesity Prescription Drugs Market Analysis
14.1 India Anti-Obesity Prescription Drugs Market Prospects
14.2 India Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
14.3 India Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
15 Italy Anti-Obesity Prescription Drugs Market Analysis
15.1 Italy Anti-Obesity Prescription Drugs Market Prospects
15.2 Italy Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
15.3 Italy Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
16 Brazil Anti-Obesity Prescription Drugs Market Analysis
16.1 Brazil Anti-Obesity Prescription Drugs Market Prospects
16.2 Brazil Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
16.3 Brazil Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
17 Mexico Anti-Obesity Prescription Drugs Market Analysis
17.1 Mexico Anti-Obesity Prescription Drugs Market Prospects
17.2 Mexico Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
17.3 Mexico Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
18 Indonesia Anti-Obesity Prescription Drugs Market Analysis
18.1 Indonesia Anti-Obesity Prescription Drugs Market Prospects
18.2 Indonesia Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
18.3 Indonesia Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
19 Vietnam Anti-Obesity Prescription Drugs Market Analysis
19.1 Vietnam Anti-Obesity Prescription Drugs Market Prospects
19.2 Vietnam Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
19.3 Vietnam Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
20 South Africa Anti-Obesity Prescription Drugs Market Analysis
20.1 South Africa Anti-Obesity Prescription Drugs Market Prospects
20.2 South Africa Anti-Obesity Prescription Drugs Market Size by Product Segment (2021-2033)
20.3 South Africa Anti-Obesity Prescription Drugs Market Size by Product Application (2021-2033)
21 Research Conclusion
22 Appendix
22.1 Methodology/Research Approach
22.2 Research Landscape
22.3 Research Benchmark and Hypothesis
22.4 Data Source
22.4.1 Primary Sources
22.4.2 Secondary Sources
22.5 Data Cross Validation
22.6 Disclaimer
Table 1：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Segment (2021 VS 2026 VS 2033) & (Million USD)
Table 2：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis by Product Application (2021 VS 2026 VS 2033) & (Million USD)
Table 3：Anti-Obesity Prescription Drugs Downstream Customers List
Table 4：Anti-Obesity Prescription Drugs Distributors/Dealers List
Table 5：Global Anti-Obesity Prescription Drugs Market Revenue by Key Players (2021-2026) & (Million USD)
Table 6：Global Anti-Obesity Prescription Drugs Market Position by Key Players
Table 7：Global Key Players Headquarter and Key Area Served
Table 8：Global Anti-Obesity Prescription Drugs Market Expansion and M&A Dynamic
Table 9：F Hoffmann La Roche Ltd Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 10：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Features
Table 11：F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 12：Orexigen Therapeutics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 13：Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Features
Table 14：Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 15：Novo Nordisk A/s Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 16：Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Features
Table 17：Novo Nordisk A/s Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 18：Arena Pharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 19：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Features
Table 20：Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 21：Glaxosmithkline Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 22：Glaxosmithkline Anti-Obesity Prescription Drugs Product Features
Table 23：Glaxosmithkline Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 24：Vivus Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 25：Vivus Anti-Obesity Prescription Drugs Product Features
Table 26：Vivus Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 27：Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 28：Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Features
Table 29：Boehringer Ingelheim Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 30：Alizyme Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 31：Alizyme Anti-Obesity Prescription Drugs Product Features
Table 32：Alizyme Anti-Obesity Prescription Drugs Revenue (Million USD) and Gross Margin (2021-2026)
Table 33：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast by Countries (2021 VS 2026 VS 2033) & (Million USD)
Table 34：Global Anti-Obesity Prescription Drugs Market Revenue by Countries (2021-2026) & (Million USD)
Table 35：Global Anti-Obesity Prescription Drugs Market Share by Countries (2021-2026)
Table 36：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Countries (2027-2033) & (Million USD)
Table 37：Global Anti-Obesity Prescription Drugs Market Share Forecast by Countries (2027-2033)
Table 38：Global Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 39：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 40：Global Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 41：Global Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 42：United States Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 43：United States Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 44：United States Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 45：United States Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 46：China Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 47：China Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 48：China Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 49：China Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 50：Germany Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 51：Germany Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 52：Germany Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 53：Germany Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 54：Japan Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 55：Japan Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 56：Japan Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 57：Japan Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 58：France Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 59：France Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 60：France Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 61：France Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 62：South Korea Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 63：South Korea Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 64：South Korea Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 65：South Korea Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 66：United Kingdom Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 67：United Kingdom Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 68：United Kingdom Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 69：United Kingdom Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 70：India Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 71：India Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 72：India Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 73：India Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 74：Italy Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 75：Italy Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 76：Italy Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 77：Italy Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 78：Brazil Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 79：Brazil Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 80：Brazil Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 81：Brazil Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 82：Mexico Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 83：Mexico Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 84：Mexico Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 85：Mexico Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 86：Indonesia Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 87：Indonesia Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 88：Indonesia Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 89：Indonesia Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 90：Vietnam Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 91：Vietnam Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 92：Vietnam Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 93：Vietnam Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 94：South Africa Anti-Obesity Prescription Drugs Market Revenue by Product Segment (2021-2026) & (Million USD)
Table 95：South Africa Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Segment (2027-2033) & (Million USD)
Table 96：South Africa Anti-Obesity Prescription Drugs Market Revenue by Product Application (2021-2026) & (Million USD)
Table 97：South Africa Anti-Obesity Prescription Drugs Market Revenue Forecast by Product Application (2027-2033) & (Million USD)
Table 98：Secondary Sources
Figure 1：Anti-Obesity Prescription Drugs Product Scope
Figure 2：Global Anti-Obesity Prescription Drugs Market Size and Growth Forecast Analysis (2021-2033) & (Million USD)
Figure 3：Global Anti-Obesity Prescription Drugs Product Segment Market Share (2026 & 2033)
Figure 4：Global Anti-Obesity Prescription Drugs Product Application Market Share (2026 & 2033)
Figure 5：Wegovy Product Scope
Figure 6：Saxenda Product Scope
Figure 7：Zepbound Product Scope
Figure 8：Xenical Product Scope
Figure 9：Others Product Scope
Figure 10：Hospitals Pharmacies Product Scope
Figure 11：Retail Pharmacies Product Scope
Figure 12：E-commerce Product Scope
Figure 13：Anti-Obesity Prescription Drugs Industrial Chain Framework
Figure 14：Global Anti-Obesity Prescription Drugs Market by Geographic Segmentation in 2026
Figure 15：Global Anti-Obesity Prescription Drugs Market Share by Countries (2021 VS 2026)
Figure 16：United States Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 17：China Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 18：Germany Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 19：Japan Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 20：France Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 21：South Korea Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 22：United Kingdom Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 23：India Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 24：Italy Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 25：Brazil Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 26：Mexico Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 27：Indonesia Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 28：Vietnam Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 29：South Africa Anti-Obesity Prescription Drugs Market Size and Growth Forecast (2025 VS 2026 VS 2033) & (Million USD)
Figure 30：Research Methodology
Figure 31：Primary Sources
Figure 32：Data Cross Validation
Global Anti-Obesity Prescription Drugs Revenue and Market Share by Key Players
| Revenue (US$ Million) | 2021 | 2022 | 2023 | 2024 | 2025 |
| F Hoffmann La Roche Ltd | XX | XX | XX | XX | XX |
| Orexigen Therapeutics | XX | XX | XX | XX | XX |
| Novo Nordisk A/s | XX | XX | XX | XX | XX |
| Arena Pharmaceuticals | XX | XX | XX | XX | XX |
| Glaxosmithkline | XX | XX | XX | XX | XX |
| Vivus | XX | XX | XX | XX | XX |
| Boehringer Ingelheim | XX | XX | XX | XX | XX |
| Alizyme | XX | XX | XX | XX | XX |
| Other Companies | XX | XX | XX | XX | XX |
| Total | XX | XX | XX | XX | XX |
English
Related Reports 
